The review found no eligible studies for this question.
It is very uncertain whether SGLT‐2 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
It is very uncertain whether GLP‐1 analogues inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
It is very uncertain whether DPP‐4 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether insulin analogues changes any adverse events other than hypoglycaemia compared with biphasic insulin (very low certainty).